Navigation Links
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Date:1/3/2012

AMSTERDAM, January 4, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B. Orphan designation in the U.S. could provide up to seven years market exclusivity on regulatory approval. Orphan designation for AMT's hemophilia program in the European Union was granted in November 2011.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients, recently published in the New England Journal of Medicine (N Engl J Med 2011; 365:2357-2365), shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"U.S. orphan designation provides additional support for our hemophilia B gene therapy program and supplements the designation in the EU received in November," said Jörn Aldag, CEO of AMT. "The early clinical success seen with the program to date by our partners is very encouraging. We will build on this success in the coming months."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicl
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MI (PRWEB) November 22, 2014 ... to simulate the proper management of life-like respiratory ... test lung devices . Grand Rapids-based, Michigan Instruments ... to donate two of the respiratory simulation units ... $15,000 each. Grand Valley and Muskegon Community College ...
(Date:11/21/2014)... HARROGATE, England , Nov. 21, 2014   TRU-D ... Ltd., will feature their superbug-killing UVC automated disinfection robot, TRU-D ... , this week from Nov. 23 to 26 at Stand ... Societies, is the United Kingdom,s largest ... 15 infection prevention societies to one of the leading events ...
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... Why did Stephen Hawking become so ... instantly recognizable? Why have they become icons to rival ... Hilton Ratcliffe seeks out the answers to those questions, ... do with science. In " Stephen Hawking Smoked My ... 2014), Ratcliffe puts it plainly: , “It is ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... Known medically as atopic dermatitis (AD), eczema is ... the affected area of skin may result in redness, ... of the skin.(2) Immuno-modulators called topical calcineurin (cal-SEE-nur-in) inhibitors ... moderate or severe eczema(3) who fail to respond adequately ...
... BETHESDA, Md., Aug. 3 Micromet, Inc. ... novel, proprietary antibodies for the treatment of cancer, inflammation ... Orphan Drug Designation from the European Medicines Agency (EMEA) ... (ALL). Blinatumomab is a novel therapeutic antibody that ...
... 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... relating to long-term treatment with Stimuvax were presented at ... 13th World Conference on Lung Cancer in San Francisco ... Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, ...
Cached Biology Technology:Five Questions About Protopic (tacrolimus) Ointment 2Five Questions About Protopic (tacrolimus) Ointment 3Five Questions About Protopic (tacrolimus) Ointment 4Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 4Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 2Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 3Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 4
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... available in French . Researchers at ... of Canada, the University of Toronto and the SETI ... highly unique spring located on Axel Heiberg Island in ... explains that the Lost Hammer spring supports microbial life, ...
... 3, 2010 A cancer conference dedicated to increased ... bridge Western and Native American approaches to disease and ... Navajos are learning about cancer, adopting measures to help ... opening up to new therapies. The 3rd annual ...
... This release is available in French . , ... Social Sciences, two teams of researchers led by Professor Barbara ... Goldsmiths, University of London, U.K., have brought research in intelligent ... have developed a highly sophisticated concept of interactive clothing whereby ...
Cached Biology News:Could life survive on Mars? Yes, expert says 23rd annual Ft. Defiance Cancer Awareness Conference set for June 5 23rd annual Ft. Defiance Cancer Awareness Conference set for June 5 3Innovative research reawakens human memories through intelligent textiles 2
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Biology Products: